Hangzhou Diagens Biotechnology Co., Ltd. ("Diagens Biotechnology" or "the Company"), a leading reproductive health company in China, recently closed a financing round of RMB 100+ million. This round was led by Grand Flight Investment, with participation from Meihong Private Fund and Yu Economic Development Equity Fund, and continued support from existing shareholder Xingjiang Liyuan Investment.

CEC Capital served as the exclusive financial advisor for Diagens Biotechnology in this transaction.

The proceeds from this financing will be utilized to further support the development of Diagens Biotechnology's Chromosome AI diagnostic technology and upstream reagents and consumables for assisted reproduction. Additionally, it will accelerate the nationwide expansion of pre-pregnancy reproductive health testing services.

Founded in 2016, Diagens Biotechnology is a leading player in the upstream segment of China's reproductive health industry. The company has developed a cutting-edge third-generation artificial intelligence chromosome analysis system, dedicated to addressing core technological challenges in human reproductive health. It provides high-tech products and services for clinical hospitals, research institutions, and the general public. With over 60 core independent intellectual property rights, its reproductive health testing and treatment products have gained high recognition in clinical applications. These products have been successfully launched in both China and the European Union, and are now available in hundreds of top-tier hospitals. The company's pioneering online platform for reproductive health testing offers precise and intelligent testing services and treatments to an annual user base of 40 million prospective parents across China.